BACKGROUND: In dogs with heart failure (HF), chronic therapy with cardiac contractility modulation (CCM) electrical signals delivered to left ventricular (LV) muscle during the absolute refractory period improves LV function. This study examined the effects of CCM therapy on the expression of calcium (Ca(2+))-binding proteins (CBPs) in dogs with HF. METHODS AND RESULTS: Studies were performed in LV tissue from seven CCM-treated HF dogs, seven untreated HF dogs, and six normal (NL) dogs. mRNA expression of S100A1, sorcin, presenillin-1 (PS1), PS2, histidine-rich Ca(2+)-binding protein (HRC), and 18S ribosomal RNA (18S), a housekeeping gene, was measured using RT-PCR. Protein levels of CBPs and calsequestrin (CSQ) were determined by Western blotting. No difference was observed in the expression of 18S and CSQ among study groups. Compared with NL, the expression of S100A1, sorcin, and HRC was decreased, whereas the expression of PS2 was increased in untreated HF dogs. CCM therapy normalized the expression of S100A1, sorcin, and PS2 but not of HRC. No change was seen in the expression of PS1 among study groups. CONCLUSION: CCM therapy restores LV expression of S100A1, PS2, and sorcin. Normalization of CBPs may partly contribute to improved LV function in HF following CCM therapy.
BACKGROUND: In dogs with heart failure (HF), chronic therapy with cardiac contractility modulation (CCM) electrical signals delivered to left ventricular (LV) muscle during the absolute refractory period improves LV function. This study examined the effects of CCM therapy on the expression of calcium (Ca(2+))-binding proteins (CBPs) in dogs with HF. METHODS AND RESULTS: Studies were performed in LV tissue from seven CCM-treated HF dogs, seven untreated HF dogs, and six normal (NL) dogs. mRNA expression of S100A1, sorcin, presenillin-1 (PS1), PS2, histidine-rich Ca(2+)-binding protein (HRC), and 18S ribosomal RNA (18S), a housekeeping gene, was measured using RT-PCR. Protein levels of CBPs and calsequestrin (CSQ) were determined by Western blotting. No difference was observed in the expression of 18S and CSQ among study groups. Compared with NL, the expression of S100A1, sorcin, and HRC was decreased, whereas the expression of PS2 was increased in untreated HF dogs. CCM therapy normalized the expression of S100A1, sorcin, and PS2 but not of HRC. No change was seen in the expression of PS1 among study groups. CONCLUSION: CCM therapy restores LV expression of S100A1, PS2, and sorcin. Normalization of CBPs may partly contribute to improved LV function in HF following CCM therapy.
Authors: D Burkhoff; I Shemer; B Felzen; J Shimizu; Y Mika; M Dickstein; D Prutchi; N Darvish; S A Ben-Haim Journal: Heart Fail Rev Date: 2001-01 Impact factor: 4.214
Authors: Kimberly N Gregory; Kenneth S Ginsburg; Ilona Bodi; Harvey Hahn; Yehia M A Marreez; Qiujing Song; Prabhu A Padmanabhan; Bryan A Mitton; Jason R Waggoner; Federica Del Monte; Woo Jin Park; Gerald W Dorn; Donald M Bers; Evangelia G Kranias Journal: J Mol Cell Cardiol Date: 2006-05 Impact factor: 5.000
Authors: S T Pleger; P Most; B Heidt; M Voelkers; J A Hata; H A Katus; A Remppis; W J Koch Journal: Eur J Med Res Date: 2006-10-27 Impact factor: 2.175
Authors: Makoto Imai; Sharad Rastogi; Ramesh C Gupta; Sudhish Mishra; Victor G Sharov; William C Stanley; Yuval Mika; Benny Rousso; Daniel Burkhoff; Shlomo Ben-Haim; Hani N Sabbah Journal: J Am Coll Cardiol Date: 2007-05-17 Impact factor: 24.094
Authors: D Müller; A Remppis; P Schauerte; S Schmidt-Schweda; D Burkhoff; B Rousso; D Gutterman; J Senges; G Hindricks; K-H Kuck Journal: Clin Res Cardiol Date: 2017-07-06 Impact factor: 5.460
Authors: Demetrios A Arvanitis; Elizabeth Vafiadaki; Daniel M Johnson; Evangelia G Kranias; Despina Sanoudou Journal: Front Physiol Date: 2018-09-27 Impact factor: 4.566
Authors: Daniele Masarone; Michelle M Kittleson; Stefano De Vivo; Antonio D'Onofrio; Ernesto Ammendola; Gerardo Nigro; Carla Contaldi; Maria L Martucci; Vittoria Errigo; Giuseppe Pacileo Journal: J Clin Med Date: 2022-10-04 Impact factor: 4.964